Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.86
ATRC's Cash to Debt is ranked higher than
66% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. ATRC: 5.86 )
Ranked among companies with meaningful Cash to Debt only.
ATRC' s 10-Year Cash to Debt Range
Min: 1.42  Med: 9.17 Max: No Debt
Current: 5.86
Equity to Asset 0.81
ATRC's Equity to Asset is ranked higher than
83% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ATRC: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
ATRC' s 10-Year Equity to Asset Range
Min: -2.52  Med: 0.66 Max: 0.87
Current: 0.81
-2.52
0.87
F-Score: 3
Z-Score: 13.83
M-Score: -2.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -13.11
ATRC's Operating margin (%) is ranked lower than
76% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.48 vs. ATRC: -13.11 )
Ranked among companies with meaningful Operating margin (%) only.
ATRC' s 10-Year Operating margin (%) Range
Min: -15700  Med: -27.23 Max: -5.41
Current: -13.11
-15700
-5.41
Net-margin (%) -13.47
ATRC's Net-margin (%) is ranked lower than
73% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. ATRC: -13.47 )
Ranked among companies with meaningful Net-margin (%) only.
ATRC' s 10-Year Net-margin (%) Range
Min: -17980  Med: -26.77 Max: -6.43
Current: -13.47
-17980
-6.43
ROE (%) -12.11
ATRC's ROE (%) is ranked lower than
72% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. ATRC: -12.11 )
Ranked among companies with meaningful ROE (%) only.
ATRC' s 10-Year ROE (%) Range
Min: -160.02  Med: -33.73 Max: -15.8
Current: -12.11
-160.02
-15.8
ROA (%) -10.18
ATRC's ROA (%) is ranked lower than
74% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. ATRC: -10.18 )
Ranked among companies with meaningful ROA (%) only.
ATRC' s 10-Year ROA (%) Range
Min: -91.98  Med: -26.42 Max: -11.04
Current: -10.18
-91.98
-11.04
ROC (Joel Greenblatt) (%) -59.99
ATRC's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. ATRC: -59.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ATRC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -289.15  Med: -127.70 Max: -30.62
Current: -59.99
-289.15
-30.62
Revenue Growth (3Y)(%) -0.30
ATRC's Revenue Growth (3Y)(%) is ranked lower than
68% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ATRC: -0.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ATRC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -29.9  Med: 1.90 Max: 915.8
Current: -0.3
-29.9
915.8
EBITDA Growth (3Y)(%) 35.20
ATRC's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. ATRC: 35.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ATRC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -62.7  Med: -23.50 Max: 120.7
Current: 35.2
-62.7
120.7
EPS Growth (3Y)(%) 20.30
ATRC's EPS Growth (3Y)(%) is ranked higher than
72% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. ATRC: 20.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ATRC' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.4  Med: -25.40 Max: 36.3
Current: 20.3
-45.4
36.3
» ATRC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ATRC Guru Trades in Q3 2014

RS Investment Management 862,738 sh (+2.26%)
Steven Cohen Sold Out
» More
Q4 2014

ATRC Guru Trades in Q4 2014

RS Investment Management 1,054,238 sh (+22.20%)
» More
Q1 2015

ATRC Guru Trades in Q1 2015

Chuck Royce 363,000 sh (New)
RS Investment Management 1,174,830 sh (+11.44%)
» More
Q2 2015

ATRC Guru Trades in Q2 2015

RS Investment Management 1,710,210 sh (+45.57%)
RS Investment Management 1,710,210 sh (+45.57%)
Chuck Royce 404,000 sh (+11.29%)
» More
» Details

Insider Trades

Latest Guru Trades with ATRC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.29
ATRC's P/B is ranked lower than
78% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. ATRC: 5.29 )
Ranked among companies with meaningful P/B only.
ATRC' s 10-Year P/B Range
Min: 0.64  Med: 4.77 Max: 14.1
Current: 5.29
0.64
14.1
P/S 5.48
ATRC's P/S is ranked lower than
76% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. ATRC: 5.48 )
Ranked among companies with meaningful P/S only.
ATRC' s 10-Year P/S Range
Min: 0.27  Med: 2.48 Max: 6.36
Current: 5.48
0.27
6.36
Current Ratio 3.01
ATRC's Current Ratio is ranked higher than
66% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. ATRC: 3.01 )
Ranked among companies with meaningful Current Ratio only.
ATRC' s 10-Year Current Ratio Range
Min: 1.43  Med: 3.23 Max: 7.58
Current: 3.01
1.43
7.58
Quick Ratio 2.48
ATRC's Quick Ratio is ranked higher than
70% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. ATRC: 2.48 )
Ranked among companies with meaningful Quick Ratio only.
ATRC' s 10-Year Quick Ratio Range
Min: 1.14  Med: 2.66 Max: 7.18
Current: 2.48
1.14
7.18
Days Inventory 154.21
ATRC's Days Inventory is ranked lower than
64% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. ATRC: 154.21 )
Ranked among companies with meaningful Days Inventory only.
ATRC' s 10-Year Days Inventory Range
Min: 38.13  Med: 132.20 Max: 160.74
Current: 154.21
38.13
160.74
Days Sales Outstanding 54.15
ATRC's Days Sales Outstanding is ranked higher than
63% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.01 vs. ATRC: 54.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATRC' s 10-Year Days Sales Outstanding Range
Min: 43.02  Med: 57.36 Max: 67.09
Current: 54.15
43.02
67.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 29.12
ATRC's Price/Net Cash is ranked lower than
71% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.72 vs. ATRC: 29.12 )
Ranked among companies with meaningful Price/Net Cash only.
ATRC' s 10-Year Price/Net Cash Range
Min: 4.55  Med: 11.57 Max: 43.11
Current: 29.12
4.55
43.11
Price/Net Current Asset Value 11.54
ATRC's Price/Net Current Asset Value is ranked lower than
68% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.89 vs. ATRC: 11.54 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATRC' s 10-Year Price/Net Current Asset Value Range
Min: 1.03  Med: 7.54 Max: 32.77
Current: 11.54
1.03
32.77
Price/Tangible Book 8.15
ATRC's Price/Tangible Book is ranked lower than
75% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. ATRC: 8.15 )
Ranked among companies with meaningful Price/Tangible Book only.
ATRC' s 10-Year Price/Tangible Book Range
Min: 0.85  Med: 5.88 Max: 16.1
Current: 8.15
0.85
16.1
Price/Projected FCF 305.75
ATRC's Price/Projected FCF is ranked lower than
99% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.76 vs. ATRC: 305.75 )
Ranked among companies with meaningful Price/Projected FCF only.
ATRC' s 10-Year Price/Projected FCF Range
Min: 9.75  Med: 20.37 Max: 308
Current: 305.75
9.75
308
Price/Median PS Value 2.26
ATRC's Price/Median PS Value is ranked lower than
90% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. ATRC: 2.26 )
Ranked among companies with meaningful Price/Median PS Value only.
ATRC' s 10-Year Price/Median PS Value Range
Min: 0.13  Med: 0.99 Max: 2.27
Current: 2.26
0.13
2.27
Earnings Yield (Greenblatt) (%) -2.55
ATRC's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ATRC: -2.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ATRC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -3.9  Med: 0.00 Max: 0
Current: -2.55
-3.9
0

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 128 148
EPS($) -0.82 -0.75
EPS without NRI($) -0.82 -0.75

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:A5I.Germany,
AtriCure Inc was incorporated in the State of Delaware as AtriCure, Inc. on October 31, 2000. It is a medical device company and engaged in developing, manufacturing and selling cardiac surgical ablation systems designed to create precise lesions, in cardiac, or heart, tissue for the treatment of atrial fibrillation, and systems for the exclusion of the left atrial appendage. It has two primary product lines for the ablation of cardiac tissue. Its primary product line for the ablation of cardiac tissue is the AtriCure Synergy Ablation System ('Synergy System'), a bipolar ablation clamp system and related radiofrequency ('RF') ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. Additionally, the Company offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System ('AtriClip System'), which is designed to safely and effectively exclude the left atrial appendage. Its products are utilized by cardiothoracic surgeons during concomitant open-heart surgical procedures and also during sole-therapy minimally invasive cardiac ablation procedures. During a concomitant open procedure, the surgeon ablates cardiac tissue and/or excludes the left atrial appendage, secondary, or concomitant, to a primary cardiac procedure such as a valve or coronary bypass. Additionally, cardiothoracic surgeons have adopted its products as a treatment alternative for AF patients who may be candidates for sole-therapy minimally invasive surgical procedures. Its Synergy System, which includes its Isolator Synergy clamps, a radiofrequency generator and related switchbox, is cleared by the FDA, for the treatment of patients with persistent and long-standing persistent AF during open-heart concomitant coronary artery bypass grafting and/or valve replacement or repair procedures. In the United States it primarily sells its products to medical centers through its direct sales force. AtriCure Europe, B.V., its wholly-owned subsidiary incorporated and based in the Netherlands, markets and sells its products throughout Europe, the Middle East and Africa, or EMEA, primarily through distributors, while in certain markets, such as Germany and the Benelux region, it sell directly to medical centers. Additionally, it sells its products to other international distributors, mainly in Asia, South America and Canada. The Company's competitors include Biosense Webster, Inc. (a subsidiary of Johnson & Johnson), St. Jude Medical, Inc., and Medtronic, Inc. Its products are medical devices and are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries.
» More Articles for ATRC

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Amyris, AtriCure, 3D Systems Corporation and Cooper Tire & Rubber Compan Sep 10 2012 
AtriCure Inc. (ATRC) President and CEO and Director David J Drachman sells 40,671 Shares Feb 25 2011 
AtriCure Inc. Reports Operating Results (10-Q) Aug 10 2010 
AtriCure Inc. Reports Operating Results (10-Q) Nov 09 2009 
AtriCure Inc. Reports Operating Results (10-Q) Aug 10 2009 
AtriCure Reports Second Quarter 2009 Financial Results Aug 04 2009 
AtriCure Inc. Reports Operating Results (10-Q) May 07 2009 
AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2008 Financial Resul Feb 09 2009 

More From Other Websites
Which of the region's stocks fared the best during Monday's stock market chaos Aug 24 2015
AtriCure to Present at the Morgan Stanley Global Healthcare Conference Aug 21 2015
AtriCure to Present at the Morgan Stanley Global Healthcare Conference Aug 21 2015
ATRICURE, INC. Financials Aug 07 2015
ABIOMED, Inc.: Leads amongst peers with strong fundamentals Aug 05 2015
10-Q for AtriCure, Inc. Aug 03 2015
ATRICURE, INC. Files SEC form 10-Q, Quarterly Report Jul 31 2015
Edited Transcript of ATRC earnings conference call or presentation 28-Jul-15 8:30pm GMT Jul 29 2015
AtriCure reports 2Q loss Jul 28 2015
AtriCure reports 2Q loss Jul 28 2015
AtriCure Reports Second Quarter 2015 Financial Results and Updates 2015 Outlook Jul 28 2015
AtriCure Inc Earnings Call scheduled for 4:30 pm ET today Jul 28 2015
ATRICURE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 28 2015
AtriCure Reports Second Quarter 2015 Financial Results and Updates 2015 Outlook Jul 28 2015
Q2 2015 AtriCure Inc Earnings Release - After Market Close Jul 28 2015
5 Hated Earnings Stocks You Should Love Jul 27 2015
AtriCure to Present at the Canaccord 35th Annual Growth Conference Jul 15 2015
AtriCure to Present at the Canaccord 35th Annual Growth Conference Jul 15 2015
AtriCure to Announce Second Quarter 2015 Financial Results Jul 07 2015
AtriCure to Announce Second Quarter 2015 Financial Results Jul 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK